Tivicay® (dolutegravir) 50-mg tablets for HIV-1
FDA has approved Viiv Healthcare’s integrase inhibitor Tivicay® (dolutegravir) 50-mg tablets, for use with other antiretroviral agents in treating HIV-1 infection. ViiV Healthcare is an HIV therapeutics company established in 2009 by GlaxoSmithKline and Pfizer. Tivicay is indicated for...Tags: HIV-1, HIV, Drug, Computational Chemistry
4053 days ago
Tags: DST-SERB, Winter School, Computational Chemistry, WSCC – 2013
3968 days ago